Ascentage Pharma Grants New RSUs to Top Executives Under 2022 Incentive Scheme

Ascentage Pharma Group International ( (HK:6855) ) has shared an announcement.

Ascentage Pharma has granted 696,263 restricted share units under its 2022 RSU Scheme to three senior personnel, including CEO and executive director Dr. Yang Dajun, chief medical officer and substantial shareholder Dr. Zhai Yifan, and a senior manager. The awards, representing about 0.19% of the company’s issued share capital, will be satisfied by issuing new shares to the scheme trustee under the existing 10% mandate limit and were approved by the board and remuneration committee, with interested directors abstaining.

The new shares linked to these RSUs will rank pari passu with existing shares and have already received listing approval from the Hong Kong Stock Exchange, supporting the company’s ongoing use of equity incentives as a key element of executive compensation. The board, including independent non-executive directors, considers the grant to be on normal commercial terms and in the interests of shareholders, signaling continued alignment between management incentives and the company’s long-term performance.

The most recent analyst rating on (HK:6855) stock is a Buy with a HK$93.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.

More about Ascentage Pharma Group International

Ascentage Pharma Group International is a biopharmaceutical company listed in Hong Kong that focuses on developing innovative cancer therapies. The group operates through its subsidiaries and relies on equity-based incentive schemes, including restricted share units and share options, to attract and retain senior scientific and managerial talent in a competitive global life sciences market.

Average Trading Volume: 2,073,352

Technical Sentiment Signal: Buy

Current Market Cap: HK$19.67B

See more data about 6855 stock on TipRanks’ Stock Analysis page.